165111-46-6

Basic information

• Product Name: Methyl 2-bromomethyl-4-cyanobenzoate
• Synonyms: Methyl 2-bromomethyl-4-cyanobenzoate
• CAS NO: 165111-46-6
• Molecular Formula: C₁₀H₈BrNO₂
• Molecular Weight: 254.08002
• Mol File: 165111-46-6.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 380.5 °C at 760 mmHg
• Flash Point: 183.9 °C
• Appearance: /
• Density: 1.53 g/cm³
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: Methyl 2-bromomethyl-4-cyanobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 2-bromomethyl-4-cyanobenzoate(165111-46-6)
• EPA Substance Registry System: Methyl 2-bromomethyl-4-cyanobenzoate(165111-46-6)

Safety Data

• Hazardous Substances Data: 165111-46-6(Hazardous Substances Data)

Usage

General Description

Methyl 2-bromomethyl-4-cyanobenzoate is a chemical compound with the molecular formula C10H8BrNO2. It is a white to off-white solid with a molecular weight of 271.08 g/mol. Methyl 2-bromomethyl-4-cyanobenzoate is commonly used as an intermediate in organic synthesis, especially in the production of pharmaceuticals and agrochemicals. It contains a bromine atom, a cyano group, and an ester group, making it a versatile building block for the synthesis of various organic compounds. Methyl 2-bromomethyl-4-cyanobenzoate is a highly reactive compound and should be handled with care due to its potential health hazards and environmental impact.

Upstream product

• 103261-67-2 4-cyano-2-methylbenzoic acid methyl ester 
• 68837-59-2 4-bromo-2-methylbenzoic acid 
• 99548-55-7 4-bromo-2-methyl-benzoic acid methyl ester 

Downstream Products

• 678992-35-3 5-[5-(6-cyano-1-oxo-1,3-dihydro-isoindol-2-ylmethyl)-3-methyl-1H-pyrazol-4yloxy]-isophthalonitrile 
• 165111-47-7 methyl 4-cyano-2-(4-hydroxyphenoxy)methylbenzoate 
• 1134082-50-0 3-(5-Cyano-1-oxoisoindolin-2-yl)benzoic acid 
• 1440519-96-9 2-(4-methoxy-benzyl)-1-oxo-2,3-dihydro-1H-isoindole-5-carbonitrile 
• 23386-40-5 1-oxo-2,3-dihydro-1H-isoindole-5-carboxylic acid 
• 1261869-76-4 1-oxoisoindoline-5-carbonitrile 
• 1010100-27-2 2-(2,6-dioxo-piperidin-3-yl)-1-oxo-2,3-dihydro-1H-isoindole-5-carbonitrile 

Relevant articles and documents

Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors

Aldosterone synthase (CYP11B2) inhibitors have been explored in recent years as an alternative therapeutic option to mineralocorticoid receptor (MR) antagonists to reduce elevated aldosterone levels, which are associated with deleterious effects on various organ systems including the heart, vasculature, kidney, and central nervous system (CNS). A benzamide pyridine hit derived from a focused screen was successfully developed into a series of potent and selective 3-pyridyl isoindolin-1-ones CYP11B2 inhibitors. Our systematic structure-activity relationship study enabled us to identify unique structural features that result in high selectivity against the closely homologous cortisol synthase (CYP11B1). We evaluated advanced lead molecules, exemplified by compound 52, in an in vivo cynomolgus monkey acute adrenocorticotropic hormone (ACTH) challenge model and demonstrated a superior 100-fold in vivo selectivity against CYP11B1.

Degradable hydrogel under physiological conditions

The present invention discloses a hydrogel that can be degraded under physiological conditions. The hydrogel includes at least one backbone moiety and an optional crosslinking moiety, and biodegradable linkers connecting backbone moieties and crosslinking moieties can be degraded by intramolecular cyclization.

Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors

Dipeptidyl Peptidase-IV (DPP-4) is a validated therapeutic target for type 2 diabetes. Aiming to interact with both residues Try629 and Lys554 in S2′ site, a series of novel uracil derivatives 1a–l and 2a–i incorporating benzoic acid moieties at the N3 position were designed and evaluated for their DPP-4 inhibitory activity. Structure-activity relationships (SAR) study led to the identification of the optimal compound 2b as a potent and selective DPP-4 inhibitor (IC50 = 1.7 nM). Docking study revealed the additional salt bridge formed between the carboxylic acid and primary amine of Lys554 has a key role in the enhancement of the activity. Furthermore, compound 2b exhibited no cytotoxicity in human hepatocyte LO2 cells up to 50 μM. Subsequent in vivo evaluations revealed that the ester of 2b robustly improves the glucose tolerance in normal mice. The overall results have shown that compound 2b has the potential to a safe and efficacious treatment for T2DM.